Nalinikanth Kotagiri

Nalinikanth Kotagiri

Auto-generated profile, based on publicly available information

Nalinikanth Kotagiri

University of Cincinnati

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 March 2015 in Nature Nanotechnology
Verified
Journal Article
Open access
PDF file
NKNalinikanth Kotagiri
Nalinikanth Kotagiri
GSGail P. Sudlow
Gail P. Sudlow
WAWalter J. Akers
Walter J. Akers
Samuel AchilefuSamuel Achilefu
Samuel Achilefu
The combination of light and photosensitizers for phototherapeutic interventions, such as photodynamic therapy, has transformed medicine and biology. However, the shallow penetration of light into tissues and the reliance on tissue oxygenation to generate cytotoxic radicals have limited the method to superficial or endoscope-accessible lesions. Here we report a way to overcome these limitations by using Cerenkov radiation from radionuclides to activate an oxygen-independent nanophotosensitizer, titanium dioxide (TiO2). We show that the administration of transferrin-coated TiO2 nanoparticles and clinically used radionuclides in mice and colocalization in tumours results in either complete tumour remission or an increase in their median survival. Histological analysis of tumour sections showed the selective destruction of cancerous cells and high numbers of tumour-infiltrating lymphocytes, which suggests that both free radicals and the activation of the immune system mediated the destruction. Our results offer a way to harness low-radiance-sensitive nanophotosensitizers to achieve depth-independent Cerenkov-radiation-mediated therapy.

1 August 2007 in Lasers in Surgery and Medicine
Verified
Journal Article
Closed access
PDF file
JKJin-Woo Kim
Jin-Woo Kim
ESEvgeny V. Shashkov
Evgeny V. Shashkov
EGEkaterina Galanzha
Ekaterina Galanzha
NKNalinikanth Kotagiri
Nalinikanth Kotagiri
VZVladimir P. Zharov
Vladimir P. Zharov

16 November 2021 in Advanced Healthcare Materials
Verified
Journal Article
Closed access
PDF file
STShindu C. Thomas
Shindu C. Thomas
TMTushar Madaan
Tushar Madaan
Nitin Sampat KambleNitin Sampat Kamble
Nitin Sampat Kamble
NSNabil A. Siddiqui
Nabil A. Siddiqui
GPGiovanni M. Pauletti
Giovanni M. Pauletti
NKNalinikanth Kotagiri
Nalinikanth Kotagiri

8 May 2025 in Gut Microbes
Verified
Journal Article
Open access
Nitin Sampat KambleNitin Sampat Kamble
Nitin Sampat Kamble
STShindu Thomas
Shindu Thomas
TMTushar Madaan
Tushar Madaan
NENadia Ehsani
Nadia Ehsani
SSSaqib Sange
Saqib Sange
NKNalinikanth Kotagiri
Nalinikanth Kotagiri
The emergence of new viral pathogens necessitates innovative antiviral therapies and vaccines. Traditional approaches, such as monoclonal antibodies and vaccines, are often hindered by resistance, limited effectiveness, and high costs. Here, we develop an engineered probiotic-based antiviral platform using Escherichia coli Nissle 1917 (EcN), capable of providing both mucosal and systemic immunity via oral administration. EcN was engineered to display anti-spike nanobodies or express the Spike-Receptor Binding Domain on its surface. Our findings reveal that EcN with nanobodies effectively inhibits the interaction between spike protein-expressing pseudoviruses and the ACE2 receptor. Furthermore, we observed the translocation of nanobodies to distant organs, facilitated by outer membrane vesicles (OMVs). The oral administration of EcN expressing spike proteins induced a robust immune response characterized by the production of both IgG and IgA, antibodies that blocked the pseudovirus-ACE2 interaction. While SARS-CoV-2 served as a model, this versatile probiotic platform holds potential for developing customizable biotherapeutics against a wide range of emerging pathogens such as influenza virus or respiratory syncytial virus (RSV) by engineering EcN to express viral surface protein or neutralizing nanobodies demonstrating its versatility as a next-generation mucosal vaccine strategy.

18 January 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
NKNalinikanth Kotagiri
Nalinikanth Kotagiri
MCMatthew L. Cooper
Matthew L. Cooper
MRMichael P. Rettig
Michael P. Rettig
CEChristopher Egbulefu
Christopher Egbulefu
JPJulie Prior
Julie Prior
Samuel AchilefuSamuel Achilefu
Samuel Achilefu
Most cancer patients succumb to disseminated disease because conventional systemic therapies lack spatiotemporal control of their toxic effects in vivo, particularly in a complicated milieu such as bone marrow where progenitor stem cells reside. Here, we demonstrate the treatment of disseminated cancer by photoactivatable drugs using radiopharmaceuticals. An orthogonal-targeting strategy and a contact-facilitated nanomicelle technology enabled highly selective delivery and co-localization of titanocene and radiolabelled fluorodeoxyglucose in disseminated multiple myeloma cells. Selective ablation of the cancer cells was achieved without significant off-target toxicity to the resident stem cells. Genomic, proteomic and multimodal imaging analyses revealed that the downregulation of CD49d, one of the dimeric protein targets of the nanomicelles, caused therapy resistance in small clusters of cancer cells. Similar treatment of a highly metastatic breast cancer model using human serum albumin-titanocene formulation significantly inhibited cancer growth. This strategy expands the use of phototherapy for treating previously inaccessible metastatic disease.

9 June 2014 in Bioconjugate Chemistry
Verified
Journal Article
Closed access
NKNalinikanth Kotagiri
Nalinikanth Kotagiri
ZLZhenyu Li
Zhenyu Li
XXXiaoxiao Xu
Xiaoxiao Xu
SMSuman Mondal
Suman Mondal
ANArye Nehorai
Arye Nehorai
Samuel AchilefuSamuel Achilefu
Samuel Achilefu